Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yiwei Chu"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies. However, autologous CAR-T cells still have notable d
Externí odkaz:
https://doaj.org/article/3b821db9babb429b95c2839304624d3a
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/143e589f37a84883a60f15f91b8cbebc
Autor:
Ying Fu, Zhiming Wang, Baichao Yu, Yuli Lin, Enyu Huang, Ronghua Liu, Chujun Zhao, Mingfang Lu, Wei Xu, Hongchun Liu, Yongzhong Liu, Luman Wang, Yiwei Chu
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The intestinal mucosal immune environment requires multiple immune cells to maintain homeostasis. Although intestinal B cells are among the most important immune cells, little is known about the mechanism that they employ to regulate immune homeostas
Externí odkaz:
https://doaj.org/article/b9591743086243c4adee94cbfc01c39e
Autor:
Ziwen Zhong, Ke Nan, Meilin Weng, Ying Yue, Wenchang Zhou, Zhiqiang Wang, Yiwei Chu, Ronghua Liu, Changhong Miao
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
B cells are well known as key mediators of humoral immune responses via the production of antibodies. Immunoglobulin A (IgA) is the most abundantly produced antibody isotype and provides the first line of immune protection at mucosal surfaces. Howeve
Externí odkaz:
https://doaj.org/article/849ea2bc75c440928c6a1581b0e8b6b3
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chimeric antigen receptors (CARs) or bispecific antibodies (bsAbs) redirected T cell against tumors is one of the most promising immunotherapy approaches. However, insufficient clinical outcomes are still observed in treatments of both solid and non-
Externí odkaz:
https://doaj.org/article/84426f97cc4d42e7ae2bf18cd8506826
Autor:
Marijke Timmers, Gils Roex, Yuedi Wang, Diana Campillo-Davo, Viggo F. I. Van Tendeloo, Yiwei Chu, Zwi N. Berneman, Feifei Luo, Heleen H. Van Acker, Sébastien Anguille
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging immunotherapeutic approach that is revolutionizing cancer treatment. The impressive clinical results obtained with CAR-T cell therapy in patients with acute lymphoblastic l
Externí odkaz:
https://doaj.org/article/49a4a6c44b2845dd97520781fda0d3e9
Autor:
Jun Liu, Hanying Zhu, Jiawen Qian, Ermeng Xiong, Lumin Zhang, Yan-Qing Wang, Yiwei Chu, Hiromi Kubagawa, Takeshi Tsubata, Ji-Yang Wang
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
The marginal zone B cells (MZB) are located at the interface between the circulation and lymphoid tissue and as a gatekeeper play important roles in both innate and adaptive immune responses. We have previously found that MZB are significantly reduce
Externí odkaz:
https://doaj.org/article/f8fab6d5b1aa4c0eb902851ed7b3249b
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
In recent years, chimeric antigen receptor (CAR) T-cell therapy has become popular in immunotherapy, particularly after its tremendous success in the treatment of lineage-restricted hematologic cancers. However, the application of CAR T-cell therapy
Externí odkaz:
https://doaj.org/article/a6fffad037cc455f888f9f4806725d06
Autor:
Yiwei Chu, Jiawen Qian, Yanqing Wang, Jun Liu, Lumin Zhang, Hiromi Kubagawa, Ji-Yang Wang, Takeshi Tsubata, Ermeng Xiong, Hanying Zhu
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology, Vol 9 (2018)
The marginal zone B cells (MZB) are located at the interface between the circulation and lymphoid tissue and as a gatekeeper play important roles in both innate and adaptive immune responses. We have previously found that MZB are significantly reduce